The IL-17/IL-23 axis is now understood to influence psoriasis, and the development of novel IL-17 inhibitor medications marks a sea change in the treatment of psoriasis. Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against IL-17RA. This article discusses the mechanism of action and the efficacy and safety profile of brodalumab presented in the literature. Brodalumab, the latest approved anti-IL-17-class medication, is the only one that exerts its effects on IL-17C as well as on IL-17A and IL-17F, blocking the shared IL-17 receptor A. In this sense, considering the recent evidence, brodalumab could have beneficial effects not only on psoriasis, but also on atopic dermatitis. It could also serve as a therapeutic alternative in patients who develop paradoxical eczematous reactions or atopic-like dermatitis during treatment with other anti-IL-17A (secukinumab, ixekizumab).
CITATION STYLE
Galluzzo, M., D’Adamio, S., Massaro, A., Piccolo, A., Bianchi, L., & Talamonti, M. (2019). Spotlight on brodalumab in the treatment of plaque psoriasis: The evidence to date. Clinical, Cosmetic and Investigational Dermatology, 12, 311–321. https://doi.org/10.2147/CCID.S165605
Mendeley helps you to discover research relevant for your work.